 |
|
Risk of Immune Thrombocytopenic Purpura and Autoimmune Hemolytic Anemia Among 120 908 US Veterans With Hepatitis C Virus Infection
Elizabeth Y. Chiao, MD, MPH;
Eric A. Engels, MD, MPH;
Jennifer R. Kramer, PhD;
Kenneth Pietz, PhD;
Louise Henderson, PhD;
Thomas P. Giordano, MD, MPH;
Ola Landgren, MD, PhD
Arch Intern Med. 2009;169(4):357-363.
Background There is emerging evidence that hepatitis C virus (HCV) infection play a role in the etiology of immune thrombocytopenia purpura (ITP) and autoimmune hemolytic anemia (AIHA), both of which are severe autoimmune cytopenias.
Methods To determine if HCV infection increases the risk for ITP and AIHA, we calculated the incidence rates of ITP and AIHA among 120 691 HCV-infected and 454 905 matched HCV-uninfected US veterans who received diagnoses during the period 1997 to 2004. After excluding individuals with a prior diagnosis of a lymphoproliferative disease, human immunodeficiency virus, or cirrhosis, we fitted Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) as measures of risks.
Results We found 296 ITP and 90 AIHA cases. Among HCV-infected vs HCV-uninfected persons, the overall incidence rates of ITP were 30.2 and 18.5 per 100 000 person-years, and for AIHA they were 11.4 and 5.0 per 100 000 person-years, respectively. Hepatitis C virus was associated with elevated risks for ITP (HR, 1.8; 95% CI, 1.4-2.3) and AIHA (HR, 2.8; 95% CI, 1.8-4.2). The ITP incidence was increased among both untreated and treated HCV-infected persons (HR, 1.7; 95%, CI, 1.3-2.2 and HR, 2.4; 95% CI, 1.5-3.7, respectively), whereas AIHA incidence was elevated only among treated HCV-infected persons (HR, 11.6; 95% CI, 7.0-19.3).
Conclusions Individuals infected with HCV are at an increased risk for ITP, whereas the development of AIHA seems to be associated with HCV treatment. It may be beneficial to test individuals newly diagnosed as having ITP for HCV infection.
Author Affiliations: Department of Medicine, Baylor College of Medicine, and the Houston Center for Quality of Care and Utilization Studies, Health Service Research and Development Service, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas (Drs Chiao, Kramer, Pietz, Henderson, and Giordano); and the National Cancer Institute, National Institutes of Health, Bethesda, Maryland (Drs Engels and Landgren).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
How I treat autoimmune hemolytic anemias in adults
Lechner and Jager
Blood 2010;116:1831-1838.
ABSTRACT
| FULL TEXT
|
